WASHINGTON – The FDA unsurprisingly rejected Arena Pharmaceuticals Inc.'s weight-loss drug lorcaserin, with the much-disputed rat data, which have been the subject of controversy over the past month, remaining at the center of the agency's concerns. (BioWorld Today) Read More
